Bloomberg to Air New to The Street Episode #683 Featuring BioVie, FLOKI, PetVivo, and NRx Pharmaceuticals

New to The Street airs on Bloomberg today at 6:30 PM EST, featuring BioVie, FLOKI, PetVivo, and NRx Pharmaceuticals. Pedro Vidal discusses FLOKI's success and user-friendly trading tools, while Jonathan Javitt talks about NRx's Citizen Petition to the FDA seeking removal of benzethonium chloride from ketamine products. Cuong Do updates on BioVie's Phase 3 clinical trials for Bezisterim in Parkinson's disease and long COVID, and John Lai discusses PetVivo's SPRYNG technology with Commonwealth.

New to The Street, one of the nation's longest-running business television brands, is set to air its 683rd episode on Bloomberg today at 6:30 PM EST. This episode will feature four dynamic companies making waves in various sectors: BioVie Inc., FLOKI, PetVivo Holdings, Inc., and NRx Pharmaceuticals, Inc. [1]

FLOKI: Pioneering Blockchain Gaming and Trading

Pedro Vidal, Chief Relationship Officer of FLOKI, will discuss the company's rapid growth and innovative trading tools. FLOKI's Trading Bot has become the leader on the BNB Chain, providing advanced, user-friendly tools for traders to maximize opportunities in the crypto market. Additionally, the Valhalla Game, introduced on Bloomberg, allows players to acquire assets that can be used in the real world. Over 100,000 Vera tokens have been minted to date, highlighting the game's explosive success [1].

NRx Pharmaceuticals: Advocating for Safer Ketamine

Jonathan Javitt, Founder, Chairman, and CEO of NRx Pharmaceuticals (NASDAQ:NRXP), will discuss the company's recent Citizen Petition to the U.S. Food and Drug Administration (FDA). NRx is seeking the removal of benzethonium chloride from all forms of ketamine sold in the United States. This preservative, known for its toxicity, is no longer allowed in hand cleansers and topical antiseptics. NRx has developed a preservative-free ketamine formulation with three-year stability and is pursuing FDA approval for a potential labeled indication for treating suicidal depression under the FDA Commissioner's National Priority Voucher Program [1].

BioVie Inc.: Innovations in Parkinson's Disease and Long COVID

Cuong Do, President and CEO of BioVie Inc. (NASDAQ:BIVI), will provide updates on the company's Phase 3 clinical trials for Bezisterim. The first trial targets newly diagnosed Parkinson's patients, potentially making Bezisterim the first new therapy for Parkinson's disease in over 50 years. The second trial focuses on long COVID, aiming to alleviate brain fog and fatigue, conditions affecting an estimated 17 million Americans. Both trials are expected to deliver top-line data in the first half of 2026 [2].

PetVivo Holdings: Advancing Equine Wellness

John Lai, CEO of PetVivo Holdings, Inc. (NASDAQ:PETV), will join Chase Chamberlin, Managing Partner at Commonwealth, to discuss their strategic partnership in the thoroughbred horse racing industry. The partnership aims to advance equine wellness by introducing PetVivo's innovative SPRYNG™ with OsteoCushion™ Technology into elite racing circles. This natural solution is designed to maintain joint health in performance horses [1].

Conclusion

New to The Street's 683rd episode promises to be an insightful and informative broadcast, showcasing the innovative work of BioVie, FLOKI, PetVivo, and NRx Pharmaceuticals. Each company is making significant strides in their respective fields, from blockchain gaming and ketamine safety to advancements in Parkinson's disease and equine wellness.

References

[1] https://www.nasdaq.com/press-release/new-street-air-show-683-bloomberg-featuring-biovie-floki-petvivo-and-nrx
[2] https://www.stocktitan.net/news/BIVI/